Get started
Heartbeam, Inc.Heartbeam, Inc.Heartbeam, Inc.

Heartbeam, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

BEAT trade ideas

ABC Bullish Earnings AMCEARNINGS ARE THIS AFTERNOON! Targets are 51.5 55.25 62.5 74.99 and if she gets over 81 then back to the drawing board The stock is already up significantly today Beat is not notorious for beating earnings so there is a lot of risk involved if you were to buy this today The environment just felt right to me but I have not purchased it. Beating around the bush on this one. "The only man who makes no mistakes is the man who never does anything. Do not be afraid to make mistakes, providing you do not make the same one twice.” BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and INR monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Corporate and Other segment focuses on the manufacture, engineering, development, and sale of non-invasive cardiac monitors and other population health management devices for healthcare companies, as well as contract manufacturing services under the BioTel Care and BioTel Alliance names. The company was founded in 1994 and is headquartered in Malvern, Pennsylvania.
NASDAQ:BEATLong
by lauralea
BEAT- BEAST is about to be unleashed...Positional/swing tradeBEAT is your prototypical aggressive growth stock- Strong future growth potential with good earning and revenue track record ... If you can overlook its debt level. This beast was tamed for a while after its share price skyrocketed from $25 to almost $80 , but it is ready to unleash its fury again. But first, I think the pullback is in the store facing key resistance lvl in confluence with ichi and BB on the weekly timeframe. In addition, short % of float is around 10%. However, it is a bullish sign when price hovers below the key resistance lvl rather than experiencing outright price rejection. My buy zone is between $45 to $55 for the positional trade. The long term trendline and S/R flip below this price range will act as a strong support. Click the like button and follow me if you like my analysis :D
NASDAQ:BEAT
by Libratus
let's BEAT it..It might be of some concern to shareholders to see the BioTelemetry, Inc. (NASDAQ:BEAT) share price down 15% in the last month. But that doesn't undermine the fantastic longer term performance (measured over five years). Indeed, the share price is up a whopping 538% in that time. So it might be that some shareholders are taking profits after good performance. But the real question is whether the business fundamentals can improve over the long term. Anyone who held for that rewarding ride would probably be keen to talk about it. See our latest analysis for BioTelemetry To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last half decade, BioTelemetry became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains. Since the company was unprofitable five years ago, but not three years ago, it's worth taking a look at the returns in the last three years, too. We can see that the BioTelemetry share price is up 446% in the last three years. During the same period, EPS grew by 68% each year. That makes the EPS growth rather close to the annualized share price gain of 76% over the same period. So you could reasonably conclude that investor sentiment towards the stock has remained pretty steady, over time. Rather, the share price has approximately tracked EPS growth. get free idea bit.ly
NASDAQ:BEATLong
by ShukriMahadi
BEAT will benefit? Encouraging Near-Term Outlook for Medical SecThe Zacks Medical Services industry comprises third-party service providers and caregivers appointed by core healthcare companies for economies of scale. The industry includes pharmacy benefit managers, contract research organizations (CRO), mobile and wireless medical technology companies, third-party testing labs, surgical facility providers and healthcare workforce solutions providers among others. Over the past few years, the healthcare industry has strategically moved from volume to value-based care. This changing pattern of care calls for efficient and better-quality facilities, thus gradually increasing the need to appoint specialized external service providers. In recent times, biotechnology and pharmaceutical companies have often been seen outsourcing clinical development and data solution services to improve quality of medical care at competitive costs. With growing importance of effective healthcare management, the medical service industry has become an integral part of the modern healthcare mechanism. Here are the industry’s three major themes: With a significant reduction in regulatory and tax burden on U.S. healthcare companies, the space is finally making progress in terms of technology adoption. This is creating opportunities for mobile and wireless medical technology companies. This apart, thanks to the specialized skills and advanced techniques of surgical facility providers, treatments are becoming less invasive with shorter recovery times. In the future, concepts like ‘bed less hospitals’ are expected to become popular. Currently, third-party laboratory testing providers and contract research organizations are also experiencing increasing demand, thanks to the growing need for complex tests, services and clinical research. For the conventional biotechnology and pharmaceutical firms, clinical trials account for the majority of their drug development costs. These firms are right now looking to outsource clinical trials to control escalating costs related to therapeutic complexities, regulatory demands, and timelines. Going by a report published in Contract Pharma, outsourcing to CROs is anticipated to witness 7.4% CAGR through 2019, with a market penetration rate of 72% by 2020. Overall, the global market for clinical trial services is forecast to grow 12% year on year to 2021 (The Business Research Company). With rising cognizance about the benefits of specialized medical caregiving, the need for healthcare workforce/staffing service providers has increased significantly. For example, the demand for nurses has increased manifold and is expected to remain high. Going by a study published by Georgetown University, the economy will create 1.6 million job openings for nurses through 2020.
NASDAQ:BEATLong
by ShukriMahadi
BEAT: Sort opportunityAn intraday high potential, Back Tested Sort Analysis. We ll try to enter into the correction of the uptrend movement tracking trend oscillators as below: Price is likely to break below the parallel channel . CCI divergences in a downtrending direction. DETAILS ON THE CHART NOTE: Entry range area above the entry point, is calculated upon 80% of the recorded pullback back tested past performances DISCLAIMER: This is a technical analysis study, not an advice or recommendation to invest money on.
NASDAQ:BEATShort
by TradingStatistics
1